肿瘤DNA甲基化缺氧特征可识别术后放化疗后远处转移高风险的HPV阴性头颈癌患者
在134例接受术后放化疗(PORT-C)的HPV阴性头颈鳞癌患者中验证肿瘤DNA甲基化缺氧特征(Hypoxia-M)。Hypoxia-M对总生存(HR=2.34,p=0.03)和远处转移(HR=4.3,p=0.001)有独立预后价值,但对局部复发无显著预后意义;Hypoxia-M状态与CD8 T细胞浸润呈负相关,整合既往生物标志物可改善患者分层。
要点
- Hypoxia-M是PORT-C后HPV阴性HNSCC患者OS和DM的独立预后因子。
- Hypoxia-M对术后局部复发无独立预后意义。
- Hypoxia-M与CD8 T细胞浸润负相关,整合其他标志物可改善分层。
核心结论
- Hypoxia-M在独立队列中验证了对PORT-C后HPV阴性HNSCC患者OS和DM的独立预后价值。
- 缺氧肿瘤在原发根治性放化疗与术后放化疗后的复发模式不同:前者以局部复发为主,后者以远处转移为主。
研究设计与样本
- 在德国癌症联盟放射肿瘤组(DKTK-ROG)多中心生物标志物试验框架内,对134例均接受PORT-C的HPV阴性HNSCC患者进行Hypoxia-M验证。
- DNA甲基化采用Illumina450K技术检测,并将Hypoxia-M与既往报道的缺氧基因表达特征(GES)、基于甲基化组的HPV非依赖复发分类器(HICR)及免疫细胞评分(CD3/CD8/PD-L1/PD1免疫组化)整合分析。
主要发现
- Hypoxia-M对总生存(OS)有独立预后价值(HR=2.34,p=0.03)。
- Hypoxia-M对远处转移(DM)有独立预后价值(HR=4.3,p=0.001)。
- Hypoxia-M对PORT-C后局部复发(LR)无显著预后意义。
- 调整年龄、性别、吸烟状态、肿瘤分期及高危特征(ECE和/或R1切除)后,Hypoxia-M仍显著。
- Hypoxia-M状态与CD8 T细胞浸润呈负相关,整合既往生物标志物可改善患者分层。
关键数值与推荐
- Hypoxia-M对OS的预后HR=2.34(p=0.03),对DM的HR=4.3(p=0.001),对LR无显著预后意义。
- 上述数值来自134例接受PORT-C的HPV阴性HNSCC患者队列。
临床怎么用
- Hypoxia-M可用于识别PORT-C后HPV阴性HNSCC患者中远处转移高风险亚组。
- Hypoxia-M可与缺氧GES、HICR及免疫细胞评分整合,辅助判断复发模式以指导个体化随访或治疗策略。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Tumor hypoxia is a predictive biomarker of treatment resistance in patients with head and neck squamous cell carcinoma (HNSCC). We previously reported the discovery of a tumor DNA methylation signature of hypoxia (Hypoxia-M), identifying HNSCC patients at risk for local recurrence (LR), all event progression, and death after primary radiochemotherapy (RCHT). We further validate Hypoxia-M in an independent cohort of HNSCC patients who underwent surgical resection followed by postoperative radiochemotherapy (PORT-C) METHODS: Hypoxia-M was validated in HPV-negative HNSCC patients (n = 134) homogeneously treated with PORT-C in the frame of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG) multicenter biomarker trial. DNA methylation was profiled using Illumina450K technology. The performance of Hypoxia-M was integrated with previously reported biomarkers, including gene expression signatures (GES) of hypoxia, a methylome-based HPV-Independent Classifier of disease Recurrence (HICR), and immune cell score using immunohistochemistry (CD3/CD8/PD-L1/PD1). RESULTS: Hypoxia-M was independently prognostic for overall survival (OS, HR = 2.34, p = 0.03) and distant metastasis (DM, HR = 4.3, p = 0.001), but not for LR after PORT-C. Hypoxia-M remained significant after adjusting for patientś age, gender, smoking status, tumor stage, and high-risk features (ECE&/R1 resection). Hypoxia-M status was inversely associated with CD8 T-cell infiltration. Patient stratification improved by integrating previously reported biomarkers, with Hypoxia-M demonstrating independent prognostic performance. CONCLUSIONS: The prognostic utility of Hypoxia-M was validated in an independent cohort. Our results highlighted a difference in recurrence patterns of hypoxic tumors treated in the primary setting (local recurrence) versus postoperatively (distant metastasis) and the utility of Hypoxia-M for identifying the main pattern of recurrence.
引用
- Tawk B, Halec G, Rein K, et al. A tumor DNA-Methylome derived signature of Hypoxia Identifies HPV-negative head and neck cancer patients at risk for distant metastasis after postoperative radiochemotherapy (PORT-C). Radiother Oncol. 2026. PMID: 41672251. doi:10.1016/j.radonc.2026.111433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。